Amortization of debt issuance costs and debt discount
987
1,028
409
0
Non-cash operating lease cost
128
643
270
185
Loss on debt extinguishment, net
-
-
-6,247
-1,103
Non-cash interest expense for deferred consideration
-
324
-
-
Non-cash expense from repurchase of preferred shares of vivasor
1,147
-
-
-
Stock-based compensation
3,595
3,629
5,643
3,256
Fair value of gloperba-elyxyb rpa liability expensed
-
-
500
-
Fair value of treasury stock expensed - tranche b and oramed note
-
-
3,557
-
Vivasor - stock-based compensation warrants
-1,164
-
-
-
Fair value of september 2025 warrants expensed - tranche b modification
-
-
3,091
-
Loss on disposition of property and equipment
-26
-
-
-
(gain) loss on derivative liability
-6,644
25,709
37,630
-58,357
Goodwill impairment
-
-
73,358
-
Loss on compound derivative of scilex-st. james loans
-6,930
-21,829
-
-
Transaction costs expensed related to semnur business combination
-
-
0
140,000
Financing costs and allocated expense for financial instruments at fair value
0
0
-7,148
3,091
Loss on fair value of debt and liability instruments
232
-33,714
-
22,031
Change in fair value of debt and liability instruments
-
-
25,351
-
Change in fair value of equity investments
-
-
5,590
-8,282
Change in fair value of digital assets
-
-
16,882
-4,702
Change in fair value of equity method investment, net
-
-
54,759
-
Change in fair value of aardvark contingent consideration
-1,535
-
-
-
Realized (gain) loss on emi
-
42,338
19,218
-
In-process research and development expense
0
0
0
510
Unrealized loss on digital assets
-
-18,064
-30,200
-
Unrealized loss on digital assets, net
-27,322
-
-
-
Unrealized loss on equity method investments carried at fair value, net
-50,737
-31,710
-
-
Realized gain on equity method investments carried at fair value, net
37,084
-
4,657
-
Realized loss on securities
5
-3,071
-199
-
Allowances for expected credit losses
73
800
-
0
Non- cash revenue
0
1,131
-
-
Allowances for expected credit losses
-
-
0
-
Gain from property in kind dividend
0
525
-
-
Other
-881
1,614
-188
98
Accounts receivables, net
-4,135
-4,597
664
-4,826
Inventory
-360
-257
-509
-1,378
Prepaid expenses and other
1,614
-614
3,523
-5,357
Other long-term assets
389
605
3
0
Accounts payable
3,779
15,812
1,768
4,497
Accrued payroll
207
631
15
-1,238
Accrued expenses
3,448
-7,805
-293
14,295
Accrued rebates and fees
8,543
15,758
18,375
20,441
Operating lease liability
508
-
-1,380
180
Other liabilities
-
3,394
-
-
Other current liabilities
-3,657
-
-
-
Other long-term liabilities
196
3
11
4
Purchase of equity securities
-
-
0
0
Net cash (used for) proceeds from operating activities
-6,737
-1,107
-17,471
8,230
Cash paid for in-process research and development, net
0
0
0
0
Purchase of patent
0
-2,900
-
-
Acquisition consideration paid in cash for romeg intangible asset acquisition
150
150
150
150
Cash paid to settle datavault obligation
-
-
9,230
-
Payment made for pa ops investment
300
200
1,000
-
Purchases of bitcoin
2
18,698
15,837
-
Purchases of digital assets
49
-
-
-
Repayments on promissory note
-660
-750
-962
-
Purchases of property and equipment
593
-
133
-
Exercise of prefunded warrant
-
-
-27
-
Proceeds from sale of property and equipment
15
-
-
-
Purchase of preferred shares of vivasor
1
299
9,000
-
Issuance of convertible note receivable for qscan
0
20,000
-
-
Sale of datavault shares for cash, net
15,941
31,392
39,606
-
Payment made for datavault licenses
-5,750
-500
-
-
Vivasor cash acquired
-
-
1,517
-
Sale of marketable securities
0
2,945
-
-
Purchase of convertible promissory note from denali
0
0
0
2
Net cash used for investing activities
8,451
-9,160
4,784
-152
Proceeds from issuance of shares under standby equity purchase agreements and atm sales agreement
-
-
0
0
Proceeds from issuance of revolving facility
-
-
0
0
Proceeds from issuance of fsf deposit
-
-
0
0
Repayment of tranche b notes principal and interest
-
0
-
-
Proceeds from issuance of tranche b notes and purchased revenue liability
-
-
0
-
Payments On Purchased Revenue Liability
-
0
-
-
Repayment of revolving facility
-
-
0
0
Transaction costs paid in connection with share repurchase
-
0
0
300
Installment payment of tranche b note
0
6,319
0
0
Excise tax paid in connection with share repurchase
-
0
0
151
Cash consideration paid in connection with warrant repurchase
-
-
0
-
Cash assumed in semnur business combination
-
-
2
33
Proceeds from issuance of shares under direct offerings
-
-
0
0
Repayment of convertible debentures
-
-
0
0
Payments of direct offering issuance costs
-
-
0
0
Repayment of tranche b notes
-
-
4,565
7,093
Payments of debt issuance costs
-
-
0
71
Cash consideration paid in connection with the repurchase of penny warrants
-
-
14,000
13,000
Transaction costs paid related to semnur business combination
-
0
-
0
Payments on purchased revenue liability
398
794
806
1,217
Proceeds from exercise of april 2024 rdo warrants and december 2024 rdo warrants
-
-
10,121
10,237
Payments for vivasor debt
1,730
745
558
-
Transaction costs paid in connection with issuance of common stock and exchange of april 2024 rdo warrants and december 2024 rdo warrants for november 2025 warrants
-
-
1,745
-
Acquisition of controlling interest in vivasor
0
1,500
-
-
Payments of deferred transaction costs related to semnur merger
-
-
-263
-
Payments for the termination of tumim purchase agreement
-
-
-2,700
-
Repurchase of preferred shares of vivasor
2,376
-
-
-
Proceeds from exercise of december 2024 rdo warrants for common stock
-
-
10,237
-
Proceeds from issuance of st james loan, net of issuance costs
0
-15,502
-21,528
-
Proceeds from stock options exercised and espp
21
-
6
0
Payments in lieu of fractional shares for reverse stock split
-
-
0
0
Net cash provided by (used for) financing activities
-4,483
9,144
17,520
-11,299
Effect of exchange rate changes on cash
-16
-481
-756
-
Net change in cash and cash equivalents
-2,785
-1,604
4,077
-3,221
Cash and cash equivalents at beginning of period
3,351
4,955
878
3,272
Cash and cash equivalents at end of period
566
3,351
4,955
878
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Time Plot
Show the time plot by selecting a row from the table.